| Literature DB >> 22114462 |
Farveen Marican Abu Backer1, Nik Raihan Nik Mustapha, Nor Hayati Othman.
Abstract
OBJECTIVE: We studied the clinicopathological parameters of adenocarcinoma arising from endocervix (ECA) and from endometrium (EMA) based on the expression of P16ink4a, P21waf1, and p27Kip1 proteins. STUDYEntities:
Mesh:
Substances:
Year: 2011 PMID: 22114462 PMCID: PMC3202089 DOI: 10.1155/2011/857851
Source DB: PubMed Journal: Infect Dis Obstet Gynecol ISSN: 1064-7449
Summary of the clinicopathological parameters in adenocarcinoma of the cervix (ECA) and adenocarcinoma of the endometrium (EMA).
| Variables of ECA | Frequency (%) of ECA | Variables of EMA | Frequency (%) of EMA |
|---|---|---|---|
| Age (years) | Age (years) | ||
| <35 | 3 (7.5) | <50 | 28 (30.4) |
| 35–54 | 22 (55.0) | 50–60 | 35 (38.0) |
| ≥55 | 15 (37.5) | >60 | 29 (31.5) |
|
| |||
| FIGO stage | FIGO stage | ||
| I | 27 (57.5) | I | 50 (54.3) |
| ll | 7 (17.5) | II | 13 (14.1) |
| lll | 5 ((12.5) | lll | 13 (14.1) |
| IV | 5 (12.5) | lV | 16 (17.4) |
|
| |||
| Histology tumor differentiation | Myometrial invasion | ||
| Well/moderate | 25 (62.5) | <1/2 | 45 (48.9) |
| Poor and Special type | 15 (37.5) | >1/2 | 47 (51.1) |
|
| |||
| Infiltration depth | Histologic grade | ||
| Inner 2/3 | 13 (32.5) | G1 | 39 (42.4) |
| Outer 1/3 or through | 27 (67.5) | G2 | 23 (25.0) |
| G3 | 30 (32.6) | ||
|
| |||
| Tumor length | Postmenopausal status | ||
| <20 mm | 11 (32.5) | Yes | 54 (58.7) |
| >20 mm | 29 (67.5) | No | 38 (41.3) |
|
| |||
| Tumor thickness | |||
| <5 mm | 4 (10.0) | ||
| >5 mm | 36 (90.0) | ||
|
| |||
| Infiltration to corpus | |||
| Yes | 17 (42.5) | ||
| No | 23 (57.5) | ||
|
| |||
| Vascular invasion | |||
| Yes | 20 (50.0) | ||
| No | 20 (50.0) | ||
|
| |||
| Lymph node invasion | |||
| Yes | 12 (30.0) | ||
| No | 28 (70.0) | ||
|
| |||
| Histologic type: | Histologic type: | ||
| Endocervical NOS | 25 (62.5) | Endometrioid | 75 (81.5) |
| Adenosquamous | 6 (15.0) | Adenosquamous | 4 (4.4) |
| Endometrioid | 5 (12.5) | Clear cell | 5 (5.4) |
| Serous | 1 (2.5) | Serous | 5 (5.4) |
| “Mixed” | 2 (5.0) | “Mixed” | 3 (3.3) |
Interrelationship* between clinicopathologic parameters in patients with adenocarcinoma of the cervix (ECA).
| Age group | Ethnic | Diagnosis | Histo grade | FIGO stage | Infiltration depth | Tumour size (diameter) | Tumor thickness | Corpus infiltration | Vascular invasion | LN invasion | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age group | — | 0.140 | 0.377 | 0.372 | 0.582 | 0.392 |
| 0.364 | 0.301 | 0.165 | 0.056 |
| Ethnic | — | 0.090 | 0.850 | 0.206 | 0.559 | 0.838 | 0.224 | 0.858 | 0.140 |
| |
| Histologic type | — |
| 0.572 | 0.191 | 0.411 | 0.586 | 0.804 | 0.744 | 0.722 | ||
| Histologic grade | — | 0.090 | 0.542 | 0.120 | 0.586 | 0.680 | 0.102 |
| |||
| FIGO stage | — | 0.330 | 0.152 | 1.000 |
|
|
| ||||
| Infiltration depth | — |
| 0.056 | 0.085 |
| 0.507 | |||||
| Tumor length | — |
| 0.230 |
| 0.076 | ||||||
| Tumor thickness | — | 0.749 | 0.292 | 0.818 | |||||||
| Corpus infiltration | — | 0.337 |
| ||||||||
| Vascular invasion | — |
| |||||||||
| LN invasion | — |
*Calculated using Chi-square.
Interrelationship* between clinicopathological parameters in patients with adenocarcinoma of endometrium (EMA).
| Age group | Menopausal status | Ethnic | Diagnosis | Histology grade | Myometrial invasion | FIGO stage | |
|---|---|---|---|---|---|---|---|
| Age group | — |
| 0.139 | 0.178 | 0.175 | 0.101 | 0.343 |
| Meno status | — | — | 0.194 | 0.270 | 0.641 | 0.062 | 0.260 |
| Ethnic | — | — | — | 0.825 | 0.703 | 0.248 | 0.026 |
| Histologic type | — | — | — | — |
| 0.213 | 0.081 |
| Histologic grade | — | — | — | — | — | 0.060 |
|
| Myometrial invasion | — | — | — | — | — | — |
|
| FIGO stage | — | — | — | — | — | — | — |
*Calculated using Chi-square.
Associations between p16INK4a expression and clinicopathologic parameter for endocervical adenocarcinoma.
| Characteristics | No. of patients | Positive, | Negative, |
|
|---|---|---|---|---|
| Age (years) | ||||
| <35 | 3 | 2 (66.7) | 1 (33.3) | 0.256 |
| 35–54 | 22 | 16 (72.7) | 6 (27.3) | |
| ≥55 | 15 | 14 (93.3) | 1 (6.7) | |
|
| ||||
| FIGO stage | ||||
| I-II | 30 | 24 (80.0) | 6 (20.0) | 1.000 |
| III-IV | 10 | 8 (80.0) | 2 (20.0) | |
|
| ||||
| Histology tumor differentiation | ||||
| Well/moderate | 25 | 18 (72.0) | 7 (28.0) | 0.102 |
| Poor | 15 | 14 (93.3) | 1 (6.7) | |
|
| ||||
| Infiltration depth | ||||
| Inner 2/3 | 13 | 9 (69.2) | 4 (30.8) | 0.237 |
| Outer 1/3 or through | 27 | 23 (85.2) | 4 (14.8) | |
|
| ||||
| Tumor size ([diameter) | ||||
| <20 mm | 11 | 8 (72.7) | 3 (27.3) | 0.479 |
| >20 mm | 29 | 24 (82.8) | 5 (17.2) | |
|
| ||||
| Tumor thickness | ||||
| <5 mm | 4 | 3 (75.0) | 1 (25.0) | 0.792 |
| >5 mm | 36 | 29 (80.6) | 7 (19.4) | |
|
| ||||
| Infiltration to corpus | ||||
| Yes | 17 | 13 (76.5) | 4 (23.5) | 0.631 |
| No | 23 | 19 (82.6) | 4 (17.4) | |
|
| ||||
| Vascular invasion | ||||
| Yes | 20 | 17 (85.0) | 3 (15.0) | 0.429 |
| No | 20 | 15 (75.0) | 5 (25.0) | |
|
| ||||
| Lymph node invasion | ||||
| Yes | 12 | 8 ( 66.7) | 4 (33.3) | 0.168 |
| No | 28 | 24 (85.7) | 4 (14.3) | |
|
| ||||
| Histologic type | ||||
| Endocervical | 25 | 20 (80.0) | 5 (20.0) | 1.000 |
| Non endocervical | 15 | 12 (80.0) | 3 (20.0) | |
Associations between P21waf1 expression and clinicopathologic parameter for adenocarcinoma of the cervix.
| Characteristics | No. of patients | Positive, | Negative, |
|
|---|---|---|---|---|
| Age (years) | ||||
| <35 | 3 | 2 (66.7) | 1(33.3) | 0.937 |
| 35–54 | 22 | 15 (68.1) | 7 (31.8) | |
| ≥55 | 15 | 11 (73.3) | 4 (33.7) | |
|
| ||||
| FIGO stage | ||||
| I-II | 30 | 23 (76.7) | 7 (23.3) | 0.111 |
| III-IV | 10 | 5 (50.0) | 5 (50.0) | |
|
| ||||
| Histology tumor differentiation | ||||
| Well/moderate | 25 | 16 (64.0) | 9 (36.0) | 0.285 |
| Poor | 15 | 12 (80.0) | 3 (20.0) | |
|
| ||||
| Infiltration depth | ||||
| Inner 2/3 | 13 | 10 (76.9) | 3 (23.1) | 0.507 |
| Outer 1/3 or through | 27 | 18 (66.7) | 9 (33.3) | |
|
| ||||
| Tumor length | ||||
| <20 mm | 11 | 7 (63.6) | 4 (36.4) | 0.589 |
| >20 mm | 29 | 21 (72.4) | 8 (27.6) | |
|
| ||||
| Tumor thickness | ||||
| <5 mm | 4 | 1 (25.0) | 3 (75.0) | 0.101 |
| >5 mm | 36 | 27 (75.0) | 9 (25.0) | |
|
| ||||
| Infiltration to corpus | ||||
| Yes | 17 | 9 (52.9) | 8 (47.1) |
|
| No | 23 | 19 (82.6) | 4 (17.4) | |
|
| ||||
| Vascular invasion | ||||
| Yes | 20 | 15 (75.0) | 5 (25.0) | 0.490 |
| No | 20 | 13 (65.0) | 7 (35.0) | |
|
| ||||
| Lymph node invasion | ||||
| Yes | 12 | 6 (50.0) | 6 (50.0) |
|
| No | 28 | 22 (78.6) | 6 (21.4) | |
|
| ||||
| Histologic type | ||||
| Endocervical | 25 | 17 (68.0) | 8 (32.0) | 0.722 |
| Non endocervical | 15 | 11 (73.3) | 4 (26.7) | |
Associations between p27Kip1 expression and clinicopathologic parameter for endocervical adenocarcinoma.
| Characteristics | No. of patients | Positive, | Negative, |
|
|---|---|---|---|---|
| Age (years) | ||||
| <35 | 3 | 2 (66.7) | 1 (33.3) | 0.292 |
| 35–54 | 22 | 7 (31.8) | 15 (68.2) | |
| ≥55 | 15 | 8 (53.3) | 7 (46.7) | |
|
| ||||
| FIGO stage | ||||
| I-II | 30 | 15 (50.0) | 15 (50.0) | 0.097 |
| III-IV | 10 | 2 (20.0) | 8 (80.0) | |
|
| ||||
| Histology tumor differentiation | ||||
| Well/moderate | 25 | 11 (44.0) | 14 (56.0) | 0.804 |
| Poor | 15 | 6 (40.0) | 9 (60.0) | |
|
| ||||
| Infiltration depth | ||||
| Inner 2/3 | 13 | 5 (38.5) | 8 (61.5) | 0.720 |
| Outer 1/3 or through | 27 | 12 (44.4) | 15 (55.6) | |
|
| ||||
| Tumor length | ||||
| <20 mm | 11 | 5 (45.5) | 6 (54.5) | 0.818 |
| >20 mm | 29 | 12 (41.4) | 17 (58.6) | |
|
| ||||
| Tumor thickness | ||||
| <5 mm | 4 | 1 (25.0) | 3 (75.0) | 0.395 |
| >5 mm | 36 | 16 (44.4) | 20 (55.6) | |
|
| ||||
| Infiltration to corpus | ||||
| Yes | 17 | 6 (35.3) | 11 (64.7) | 0.428 |
| No | 23 | 11 (47.8) | 12 (52.2) | |
|
| ||||
| Vascular invasion | ||||
| Yes | 20 | 7 (35.0) | 13 (65.0) | 0.337 |
| No | 20 | 10 (50.0) | 10 (50.0) | |
|
| ||||
| Lymph node invasion | ||||
| Yes | 12 | 2 (16.7) | 10 (83.3) |
|
| No | 28 | 15 (53.6) | 13 (46.4) | |
|
| ||||
| Histologic type | ||||
| Endocervical | 25 | 9 (36.0) | 16 (64.0) | 0.283 |
| Non endocervical | 15 | 8 (53.3) | 7 (46.7) | |
Associations between P16INK4a expression and clinicopathologic parameter for endometrial adenocarcinoma.
| Characteristics | No. patients | Positive, | Negative, |
|
|---|---|---|---|---|
| Age (years) | ||||
| <50 | 28 | 5 (17.9) | 23 (82.1) | 0.148 |
| 50–60 | 35 | 7 ( 20.0) | 28 (80.0) | |
| >60 | 29 | 11 (38.0) | 18 (62.0) | |
|
| ||||
| FIGO stage | ||||
| I | 50 | 12 (24.0) | 38 (76.0) | 0.809 |
| II–IV | 42 | 11 (26.2) | 31 (73.8) | |
|
| ||||
| Myometrial invasion | ||||
| <1/2 | 45 | 9 (20.0) | 36 (80.0) | 0.278 |
| >1/2 | 47 | 14 (29.8) | 33 (70.2) | |
|
| ||||
| Histologic grade | ||||
| G1-G2 | 62 | 11 (17.7) | 51 (82.2) |
|
| G3 | 30 | 12 (40.0) | 18 (60.0) | |
|
| ||||
| Postmenopausal status | ||||
| Yes | 54 | 16 (29.6) | 38 (70.4) | 0.222 |
| No | 38 | 7 (18.4) | 31 (81.6) | |
|
| ||||
| Histologic type | ||||
| Endometrioid | 75 | 16 (21.3) | 59 (78.7) | 0.888 |
| Non endometrioid | 17 | 7 (41.2) | 10 (58.8) | |